Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial

Uro-Oncology

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Prostate.

Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST, Mahal BA, Nguyen PL, Yang DD, Muralidhar V

doi: 10.1002/pros.24041.

Further Publications Urology

Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study

Prostate Cancer Prostatic Dis

Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, Yee CH, Teoh JY, Hou SM, Roobol M, Ng CF, Chiu PK

doi: 10.1038/s41391-021-00444-y

Uro-Oncology

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Eur Urol.

Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC, ProtecT Study Group.

doi: 10.1016/j.eururo.2019.10.030.

Uro-Oncology

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

BJU Int.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ

doi: 10.1111/bju.13676.

Uro-Oncology

Exercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation therapy: a randomised controlled trial

BJU Int.

Ndjavera W, Orange ST, O'Doherty AF, Leicht AS, Rochester M, Mills R, Saxton JM

doi: 10.1111/bju.14922.

Uro-Oncology

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study

Eur Urol.

Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A

doi: 10.1016/j.eururo.2019.09.027.

Uro-Oncology

External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer

J Urol.

Saba K, Wettstein MS, Lieger L, Hötker AM, Donati OF, Moch H, Ankerst DP, Poyet C, Sulser T, Eberli D, Mortezavi A

doi: 10.1097/JU.0000000000000622.

Uro-Oncology

External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer

J Urol.

Daskivich TJ, Thomas IC, Luu M, Shelton JB, Makarov DV, Skolarus TA, Leppert JT

doi: 10.1097/JU.

Uro-Oncology

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Prostate Cancer Prostatic Dis.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY

doi: 10.1038/pcan.2016.58.

Related content

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

Exercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation therapy: a randomised controlled trial

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study

External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer

External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer